Ace the CPHON Challenge 2026 – Elevate Your Pediatric Oncology Nursing Game!

Hydroxyurea is commonly used in the treatment of various hematological conditions, particularly in patients with sickle cell disease and certain types of cancer. One of the primary mechanisms of action of hydroxyurea is myelosuppression, which refers to the suppression of bone marrow activity. This results in a decrease in the production of blood cells, including leukocytes (white blood cells). Consequently, patients undergoing treatment with hydroxyurea may experience decreased leukocyte counts, putting them at increased risk for infections due to a lower immune response.

The myelosuppressive effects can also lead to a range of other hematological changes, such as anemia and thrombocytopenia (low platelet counts). Since hydroxyurea affects the bone marrow and blood cell production, careful monitoring of blood counts during treatment is essential to manage potential complications.

Understanding the side effects associated with hydroxyurea helps healthcare providers prepare for and mitigate its impacts on a patient’s health, ensuring that the benefits of treating the underlying condition outweigh risks associated with treatment.